History | Trametinib in combination with dabrafenib for treating unresectable or metastatic melanoma | Guidance | NICE

History

A list of downloadable documents created during development.

Final appraisal determination

Final appraisal determination
Final appraisal determination document ^{PDF 342 KB} 29 April 2016
Committee papers ^{PDF 10.71 MB} 29 April 2016

Consultation documents published: - scope consultation

Final scope ^{PDF 108 KB} 12 October 2015
Final matrix ^{PDF 101 KB} 12 October 2015
NICE's response to comments on the draft scope and provisional matrix ^{PDF 208 KB} 12 October 2015
Equality impact assessment (Scoping) ^{PDF 121 KB} 12 October 2015

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope (rescope)

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope (rescope) ^{PDF 114 KB} 21 August 2015

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix (rescope)

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix (rescope) ^{PDF 97 KB} 20 August 2015

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft scope ^{PDF 107 KB} 25 September 2013

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix

Melanoma (BRAF V600E mutation positive, unresectable, metastatic) - dabrafenib and trametinib: draft matrix ^{PDF 105 KB} 25 September 2013